We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Urine Test for Bowel Cancer to Reveal Presence of Early Tumors

By LabMedica International staff writers
Posted on 29 Jan 2024

Currently, the only way to diagnose bowel cancer is through a fecal occult blood test (FOBT), which identifies invisible blood traces in stool samples. More...

Now, researchers have made significant strides in developing an alternative, non-stool-based method for detecting bowel cancer by engineering a probiotic bacteria known for its efficacy in treating gut disorders. This new approach could enable early tumor detection via a urine test.

For their study, researchers from SAHMRI in Adelaide, Australia focused on a specific bacteria, Escherichia coli Nissle. This strain was originally isolated from the gut of a German soldier in 1917 by Alfred Nissle, a German physician. During World War I, when dysentery was widespread, Nissle identified this unique strain from the soldier who seemed immune to the illness. It was later found to combat harmful bacteria and has since been safely used in people. Interestingly, recent findings have shown that Escherichia coli Nissle has a natural propensity to inhabit tumors rather than normal tissue in the gut and actively seeks them out.

In their latest study, the team discovered that after being orally administered, these bacteria selectively reside in both benign precursor lesions to bowel cancer, known as polyps, and in bowel cancers themselves. Leveraging this bacteria's innate tendency to migrate toward tumors, the researchers modified it to emit molecules that could highlight early-stage cancers. This innovation paves the way for early, non-invasive cancer diagnosis. Upon reaching the tumor, the bacteria release a marker detectable in urine, indicating the presence of cancer. In the future, the researchers are aiming to be able to detect this marker in a blood test. The team also believes that this bacteria can be further modified to deliver targeted therapeutic treatments directly to the tumor site. This approach could offer an alternative treatment for early cancers while significantly reducing the side effects associated with current drug delivery methods.

"We were excited to see that the tumor-homing capability of these probiotic bacteria may also occur in people, just as in our experimental models,” said Dr. Dan Worthley from SAHMRI.

Related Links:
SAHMRI 


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.